Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Depletion of ‘Traitor’ Immune Cells Slows Cancer Growth in Mice

Published: Wednesday, September 25, 2013
Last Updated: Wednesday, September 25, 2013
Bookmark and Share
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably.

Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person’s own immune system to attack the cancer itself.

Now, scientists at the University of Washington have developed a strategy to slow tumor growth and prolong survival in mice with cancer by targeting and destroying a type of cell that dampens the body’s immune response to cancer. The researchers published their findings the week of Sept. 16 in the Proceedings of the National Academy of Sciences.

“We’re really enthusiastic about these results because they suggest an alternative drug target that could be synergistic with current treatments,” said co-author Suzie Pun, a UW associate professor of bioengineering.

Our immune system normally patrols for and eliminates abnormal cells. Macrophages are a type of helpful immune cell that can be converted to the “dark side” by signals they receive from a tumor. When inside a tumor, macrophages can switch from helping the immune system to suppressing the body’s immune response to cancer. Several studies show a correlation between the number of macrophages in tumor biopsies and poor prognosis for patients, Pun said.

The UW team developed a method to target and eliminate the cancer-supporting macrophages in mouse tumors. Researchers predict this strategy could be used along with current treatments such as chemotherapy for cancer patients.

“We think this would amplify cancer treatments and hopefully make them better,” Pun said.

Scientists have a strong understanding of the behavior of macrophages in tumors, but most current methods to remove them do away with all macrophages in the body indiscriminately instead of targeting only the harmful ones that live in tumors.

In this study, UW bioengineering doctoral student Maryelise Cieslewicz designed a method to find a specific amino-acid sequence – or a peptide – that binds only the harmful macrophages in tumors and ignores helpful ones in the bodies of mice. When this sequence was injected into mice with cancer, the research team found that the peptide collected in the macrophage cells within tumors, leaving alone other healthy organs.

Once they discovered they could deliver the peptide sequence to specific cells, the researchers attached another peptide to successfully kill the harmful macrophages without affecting other cells. The mice had slower tumor growth and better survival when treated with this material.

The research team plans to test this method with existing cancer drugs to hopefully boost the success of other treatments.

The peptide sequence that successfully bound to harmful macrophages in mice doesn’t bind to their counterparts in humans, Pun said, but the researchers expect soon to find a similar peptide that targets human cells. They plan to use this method to investigate treatments for other types of cancer, including breast and pancreatic cancers.

The Pun research team collaborated with the UW labs of Elaine Raines in pathology and André Lieber in medical genetics on this study.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Antibody Pries Loose Bacteria’s Grip
Study finds novel method of improving antibody efficacy.
Monday, May 18, 2015
Scientific News
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!